Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

20201,152 citationsJournal Article

Authors

Takashi Kojima · National Cancer Center Hospital East

Manish A. Shah · Cornell University

Kei Muro · Aichi Cancer Center

Éric François · Centre Antoine Lacassagne

Antoine Adenis · Inserm

Chih‐Hung Hsu · National Taiwan University Hospital

Toshihiko Doi ·

Abstract

Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with PD-L1 CPS ≥ 10, with fewer treatment-related adverse events.

Topics & Keywords

Esophageal Cancer Research and Treatment Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 35, pp. 4138-4148

DOI: 10.1200/jco.20.01888

Field-Weighted Citation Impact: 151.53